Fig. 3From: Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trialsForest plot showing overall survival in PARP inhibitor arm (case) and chemotherapy (placebo) arm in platinum-resistant ovarian cancer (control)Back to article page